Vanta Bioscience Complete Financial Statements
In FY2023, Vanta Bioscience (VANTABIO) reported revenue ₹1 Cr, net profit ₹-1 Cr and EPS ₹0.00, with a net profit margin of -100.0% and ROE of -25.0%. Full financial statements from FY2019 to FY2025 (7 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see Vanta Bioscience share price today.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
VANTABIO Revenue, Net Profit & EBITDA — Year-on-Year Growth
VANTABIO YoY (Mar 2022 vs Mar 2023) — revenue -80.0%, EBITDA -150.0%.
VANTABIO Income Statement — Revenue, EBITDA & Net Profit
Vanta Bioscience revenue ₹1 Cr, EBITDA ₹-1 Cr, net profit ₹-1 Cr, EPS ₹0.00 (2023) — net profit margin -100.0%. Explore VANTABIO Benjamin Graham valuation to estimate fundamental worth using multiple valuation models.
| Particulars | Mar 2023 | Mar 2022 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|
| Revenue | 1 | 5 | 3 | 0 |
| Expenses | 2 | 2 | 3 | 0 |
| EBITDA | -1 | 2 | -1 | 0 |
| Operating Profit Margin % | -206.00% | 46.00% | -20.00% | 0.00% |
| Depreciation | 0 | 1 | 1 | 0 |
| Interest | 1 | 1 | 3 | 0 |
| Profit Before Tax | -2 | 1 | -4 | 0 |
| Tax | 0 | 0 | -2 | 0 |
| Net Profit | -1 | 0 | -3 | 0 |
| Earnings Per Share (₹) | 0.00 | 0.11 | -4.06 | 0.00 |
VANTABIO Balance Sheet — Assets, Liabilities & Shareholders' Equity
VANTABIO total assets ₹86 Cr, total equity ₹4 Cr, total liabilities ₹ Cr (2025) — ROE -25.0%.
| Particulars | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Total Assets | 86 | 85 | 85 | 81 | 70 | 49 | 39 |
| Current Assets | 15 | 17 | 15 | 15 | 20 | 20 | 17 |
| Fixed Assets | 56 | 54 | 57 | 36 | 29 | 21 | 18 |
| Capital Work in Progress | 14 | 13 | 11 | 29 | 19 | 7 | 4 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Other Assets | 17 | 19 | 17 | 17 | 21 | 21 | 16 |
| LIABILITIES | |||||||
| Total Liabilities | |||||||
| Current Liabilities | 56 | 50 | 48 | 34 | 29 | 14 | 13 |
| Non-Current Liabilities | |||||||
| SHAREHOLDERS' EQUITY | |||||||
| Total Equity | 4 | 13 | 19 | 29 | 26 | 25 | 23 |
| Share Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves & Surplus | 4 | 9 | 11 | 18 | 18 | 17 | 16 |
VANTABIO Cash Flow Statement — Operating, Investing & Financing
Vanta Bioscience operating cash flow ₹-2 Cr, investing ₹-7 Cr, financing ₹9 Cr, net cash flow ₹0 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 |
|---|---|---|---|---|---|---|---|
| Operating Activities | -2 | 3 | -1 | 5 | 7 | 2 | -1 |
| Investing Activities | -7 | -3 | -6 | -17 | -22 | -8 | -6 |
| Financing Activities | 9 | 1 | 6 | 10 | 18 | 2 | 10 |
| Net Cash Flow | 0 | 0 | 0 | -2 | 3 | -3 | 3 |